Effects of a Dementia-friendly Program
Launched by UNIVERSITY HOSPITAL, AKERSHUS · Jan 29, 2021
Trial Information
Current as of April 29, 2025
Completed
Keywords
ClinConnect Summary
Study design This study, has a non-equivalent control group design and a historical control Group. The Control group received usual care and the experimental group received usual care plus the dementia-friendly program.
One Group received care after implementing the dementia-friendly hospital program. The study is performed at two medical wards at a large acute-care hospital in Norway. A medical pulmonary ward and a cardiac ward participated.
Data Collection:
Demographic data included age, gender, place of residence (home, adapted housing, institution), and family/relative network, and w...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Patients ≥75 years
- • acute admission to the cardiac or pulmonary wards.
- • Patient who has given informed written consent, or proxy consent from relatives for patients who lacked cognitive capacity.
- Exclusion Criteria:
- • Readmitted patients enrolled in a previous hospital stay.
- • Patients who do not have sufficient verbal function or hearing to communicate
- • Patients in a coma or too ill to participate
- • Patients who are isolated
- • Patients who do not wish to participate or relatives who do not want the patient to participate, in the cases where the patient lacked cognitive capacity to consent.
About University Hospital, Akershus
University Hospital Akershus is a leading clinical research institution dedicated to advancing medical knowledge and improving patient care through innovative trials. As a part of the University of Oslo, the hospital integrates cutting-edge research with clinical practice, fostering collaboration among multidisciplinary teams of healthcare professionals and researchers. With a strong emphasis on ethical standards and patient safety, University Hospital Akershus is committed to conducting high-quality clinical trials that address critical health challenges and contribute to the development of new therapies and treatments.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Lørenskog, , Norway
Patients applied
Trial Officials
Nina M Weldingh, Master
Principal Investigator
University Hospital, Akershus
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials